Clinical Trial Services Market

The clinical trial services market is projected to reach USD 97.41 billion by 2031 from USD 66.20 billion in 2026, at a CAGR of 8.0% during the forecast period of 2026 to 2031. The factors driving the growth of the clinical trial services market include the increasing complexity and sustained volume of outsourced Phase I–IV clinical trials, particularly in specialty therapeutic areas; the growing adoption of patient- and site-centric approaches, including decentralized and hybrid clinical trials; and the flexibility offered by CROs through full-service, FSP, and hybrid outsourcing models. Growth is further supported by expanding pharmaceutical and biopharmaceutical R&D pipelines and sponsors’ increasing reliance on CROs for site management and monitoring, patient recruitment, data management, pharmacovigilance, laboratory services, and other trial-execution activities. Key opportunities include regulatory modernization and innovative trial designs, greater use of AI, automation, and data analytics in clinical development, and wider adoption of decentralized and patient-centric trial models. However, patient recruitment and retention challenges, along with shortages of qualified clinical research professionals and specialized expertise, can delay study execution, increase costs, and constrain market growth.

The global CRO services market is competitive, with leading players contributing a significant share, including IQVIA Inc. (US) and ICON Plc. (Ireland), Thermo Fisher Scientific Inc. (US), Laboratory Corporation of America Holdings (LabCorp) (US), WuXi AppTec Co., Ltd. (China), Pharmaron Beijing Co., Ltd. (China), Medpace, Inc. (US), and Eurofins Scientific (Luxembourg), among others. These market players have pursued acquisitions, agreements, collaborations, and geographic expansion to strengthen their positions in the global clinical trial services market.

To know about the assumptions considered for the study download the pdf brochure

IQVIA Inc. (US)

IQVIA Inc. is a global leader in clinical research services, distinguished by its blend of large-scale healthcare data, advanced analytics, and technology-enabled trial delivery. The company’s strategic focus is accelerating Phase I to IV execution through site & patient network orchestration, decentralized & hybrid trial models, and AI-driven feasibility, recruitment, and monitoring. Its portfolio spans clinical operations, medical writing, pharmacovigilance, and post-approval studies, integrated with real-world evidence and regulatory strategy support. IQVIA continues to invest in digital patient engagement, remote assessments, and risk-based quality management to streamline timelines and improve data integrity. For instance, in March 2026, IQVIA launched IQVIA.ai, a Unified Agentic AI Platform powered by NVIDIA to improve efficiency and decision-making across life sciences.

ICON plc (Ireland)

ICON plc is a leading provider of outsourced clinical trial services, offering integrated and flexible solutions across Phase I–IV clinical development for pharmaceutical, biotechnology, and medical device sponsors. Its capabilities span early-phase clinical research, study start-up, feasibility and site identification, site management and monitoring, patient recruitment, clinical data management and biostatistics, medical writing, pharmacovigilance, and regulatory support, delivered through both full-service and functional-service models. ICON has particular clinical-development expertise in oncology, rare diseases, vaccines, infectious diseases, and advanced therapies, supported by global site networks and data-driven trial-planning capabilities. ICON is also increasing its use of AI and digital technologies across study design, feasibility, site selection, start-up, monitoring, data review, and regulatory documentation through its Orbis platform.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific, through its PPD clinical research business, is a major provider of outsourced Phase I–IV clinical trial services to pharmaceutical and biotechnology companies. Its clinical development offering includes early-phase studies, Phase II–IV trial management, site management and monitoring, patient recruitment and engagement, clinical data management, biostatistics, pharmacovigilance, regulatory support, and decentralized and hybrid trial solutions. The company continues to invest in patient-centric and technology-enabled trial delivery through eConsent, eCOA/ePRO, wearables, remote visits, AI-enabled recruitment, and risk-informed monitoring tools. In May 2026, Thermo Fisher was recognized as a leader among CROs for using AI in clinical trials, particularly across clinical development, patient engagement, pharmacovigilance, and advanced analytics.

Market Ranking

The clinical trial services market is competitive. The top five players for each market hold >35%, and the top ten account for a share of ~45–50%. 

IQVIA maintains a strong position in the clinical trial services market through its broad portfolio of outsourced Phase I–IV services, extensive global site and patient networks, and increasing use of AI, advanced analytics, and technology-enabled trial delivery. ICON plc has established a significant presence in the clinical trial services market through its end-to-end clinical development capabilities and flexible full-service, FSP, and hybrid delivery models, supported by expertise across multiple therapeutic areas and complex global studies. Thermo Fisher Scientific Inc., through PPD, Inc., also holds a strong market position, supported by an integrated clinical development offering spanning early- to late-phase trial execution, site management and monitoring, patient recruitment, data management, pharmacovigilance, laboratory and bioanalytical services, and clinical trial supply capabilities.

Related Reports:

Clinical Trial Services Market by Type (Lab, Monitoring, Contracts, Recruitment, PV, Biostatistics), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]